https://rsh.craig-hallum.com/research/-/rf/d/ipreo/4005101569/1669127534/c28029ae-ea1f-4410-b967-bc7292ce80c7.pdf
BTIG Downgrades Magenta Therapeutics to Neutral
BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.